Xenetic Biosciences, Inc.
XBIO
$2.52
-$0.07-2.70%
| Weiss Ratings | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Good | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 1.40 | |||
| Price History | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -22.94% | |||
| 30-Day Total Return | -37.45% | |||
| 60-Day Total Return | -41.44% | |||
| 90-Day Total Return | -37.20% | |||
| Year to Date Total Return | -37.78% | |||
| 1-Year Total Return | -42.73% | |||
| 2-Year Total Return | -42.82% | |||
| 3-Year Total Return | -76.88% | |||
| 5-Year Total Return | -69.31% | |||
| 52-Week High % Change | -50.19% | |||
| 52-Week Low % Change | 14.60% | |||
| Price | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $5.20 | |||
| 52-Week Low Price | $2.26 | |||
| 52-Week Low Price (Date) | Apr 02, 2025 | |||
| 52-Week High Price (Date) | Aug 05, 2024 | |||
| Valuation | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 3.99M | |||
| Enterprise Value | -2.17M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -2.57 | |||
| Earnings Per Share Growth | -4.89% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 1.60 | |||
| Price/Book (Q) | 0.67 | |||
| Enterprise Value/Revenue (TTM) | -0.87 | |||
| Price | $2.52 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | 0.52 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.54M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 778 7720 | |||
| Address | 945 Concord Street Framingham, MA 01701 | |||
| Website | www.xeneticbio.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -168.16% | |||
| Profit Margin | -158.39% | |||
| Management Effectiveness | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -30.02% | |||
| Return on Equity | -- | |||
| Income Statement | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.50M | |||
| Total Revenue (TTM) | 2.50M | |||
| Revenue Per Share | $1.62 | |||
| Gross Profit (TTM) | 2.50M | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -4.20M | |||
| Net Income (TTM) | -3.96M | |||
| Net Income Avl. to Common (TTM) | -3.96M | |||
| Total Revenue Growth (Q YOY) | -3.45% | |||
| Earnings Growth (Q YOY) | 9.99% | |||
| EPS Diluted (TTM) | -2.57 | |||
| EPS Diluted Growth (Q YOY) | 10.19% | |||
| Balance Sheet | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 6.17M | |||
| Cash Per Share (Q) | $4.00 | |||
| Total Current Assets (Q) | 6.59M | |||
| Total Preferred Equity (Q) | 0.00 | |||
| Total Equity (Q) | 6.01M | |||
| Current Ratio (Q) | 7.366 | |||
| Book Value Per Share (Q) | $3.89 | |||
| Total Assets (Q) | 6.90M | |||
| Total Current Liabilities (Q) | 894.30K | |||
| Total Debt (Q) | 0.00 | |||
| Total Liabilities (Q) | 894.30K | |||
| Total Common Equity (Q) | 6.01M | |||
| Cash Flow | XBIO - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -- | |||
| Net Change in Cash (TTM) | -2.82M | |||
| Levered Free Cash Flow (TTM) | -2.19M | |||
| Cash from Operations (TTM) | -2.82M | |||
